Dr Kevin Eggan named as Group Vice President, Head of Research and Early Development at BioMarin

pharmafile | October 9, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kevin Eggan, appointments 

BioMarin Pharmaceutical has welcomed Dr Kevin Eggan as its new Group Vice President, Head of Research and Early Development. He took up to the position on 5 October.

Dr Eggan brings almost two decades of experience in rare neurological disorder research to the role, where he will oversee the operation of BioMarin’s research projects and development of its product pipeline. His overarching goal will be cementing BioMarin’s expertise in the genetic medicine space.

Dr Eggan has held a number of high-profile roles at a number of illustrious institutions including Harvard University as a tenured Professor in the Department of Stem Cell and Regenerative Biology, Director of Stem Cell Biology for the Stanley Center for Psychiatric Research at the Broad Institute, and an Institute Member of the Broad Institute of MIT and Harvard. Additionally, he has also served on the Scientific Advisory Boards at Roche, Ipierian and Angelini Pharma among others.

Beyond his numerous roles, Dr Eggan is also the author of around 130 scientific papers and the holder of 12 patents.

“Throughout his career, Kevin has demonstrated a consistent track record of groundbreaking scientific research.  His philosophy of ‘Dish to Bedside’ illustrates how optimising basic pre-clinical models can enhance therapeutic candidates and selection of trial participants,” remarked Dr Lon Cardon, Chief Scientific Strategy Officer, Senior Vice President at BioMarin.  “Kevin comes to BioMarin at an exciting time as our understanding of genetics and biology serve as the underpinnings of BioMarin’s strategic vision to deliver transformational therapies that meaningfully change the course of rare genetic diseases.”

Related Content

Sanofi axes four major players from its executive committee

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …


Dr Richard Torbett is named as the new Chief Executive of the ABPI

The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …


Insys Therapeutics names current CFO Andrew Long as company’s new CEO

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …

Latest content